ATE425255T1 - Antagonistische antikörper gegen ve-cadherin ohne negative effekte auf die vaskuläre permeabilität - Google Patents

Antagonistische antikörper gegen ve-cadherin ohne negative effekte auf die vaskuläre permeabilität

Info

Publication number
ATE425255T1
ATE425255T1 AT01922997T AT01922997T ATE425255T1 AT E425255 T1 ATE425255 T1 AT E425255T1 AT 01922997 T AT01922997 T AT 01922997T AT 01922997 T AT01922997 T AT 01922997T AT E425255 T1 ATE425255 T1 AT E425255T1
Authority
AT
Austria
Prior art keywords
cadherin
human
antibody
antibodies against
negative effects
Prior art date
Application number
AT01922997T
Other languages
German (de)
English (en)
Inventor
Fang Liao
Daniel Hicklin
Peter Bohlen
Original Assignee
Imclone Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Systems Inc filed Critical Imclone Systems Inc
Application granted granted Critical
Publication of ATE425255T1 publication Critical patent/ATE425255T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01922997T 2000-03-31 2001-03-30 Antagonistische antikörper gegen ve-cadherin ohne negative effekte auf die vaskuläre permeabilität ATE425255T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54096700A 2000-03-31 2000-03-31

Publications (1)

Publication Number Publication Date
ATE425255T1 true ATE425255T1 (de) 2009-03-15

Family

ID=24157649

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01922997T ATE425255T1 (de) 2000-03-31 2001-03-30 Antagonistische antikörper gegen ve-cadherin ohne negative effekte auf die vaskuläre permeabilität

Country Status (12)

Country Link
US (4) US7371574B2 (cg-RX-API-DMAC7.html)
EP (1) EP1268799B1 (cg-RX-API-DMAC7.html)
JP (1) JP2003529370A (cg-RX-API-DMAC7.html)
AT (1) ATE425255T1 (cg-RX-API-DMAC7.html)
AU (1) AU2001249737A1 (cg-RX-API-DMAC7.html)
CA (1) CA2404576A1 (cg-RX-API-DMAC7.html)
CY (1) CY1109097T1 (cg-RX-API-DMAC7.html)
DE (1) DE60137915D1 (cg-RX-API-DMAC7.html)
DK (1) DK1268799T3 (cg-RX-API-DMAC7.html)
ES (1) ES2323938T3 (cg-RX-API-DMAC7.html)
PT (1) PT1268799E (cg-RX-API-DMAC7.html)
WO (1) WO2001075109A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7481999B2 (en) 1998-05-05 2009-01-27 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin-mediated function
CA2506037A1 (en) 2002-11-14 2004-06-10 Adherex Technologies, Inc. Compounds and methods for modulating desmosomal and atypical cadherin-mediated cell adhesion
JP2004175689A (ja) * 2002-11-25 2004-06-24 Kureha Chem Ind Co Ltd 癌転移抑制剤
US20040167076A1 (en) 2003-02-14 2004-08-26 Stamer W. Daniel Modulation of aqueous humor outflow by targeting vascular-endothelial-cadherin in schlemm's canal cells
GB0602063D0 (en) 2006-02-02 2006-03-15 Univ Manchester Cell Culture
US9207242B2 (en) * 2008-10-09 2015-12-08 The University Of Hong Kong Cadherin-17 as diagnostic marker and therapeutic target for liver cancer
WO2011071541A2 (en) * 2009-12-11 2011-06-16 The Scripps Research Institute Cadherin modulatory agents

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5036003A (en) * 1987-08-21 1991-07-30 Monsanto Company Antibodies to VPF
WO1993008210A1 (en) * 1991-10-18 1993-04-29 Beth Israel Hospital Association Vascular permeability factor targeted compounds
US5776427A (en) * 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
DE69332948T2 (de) * 1992-03-05 2003-11-27 Board Of Regents, The University Of Texas System Verwendung von Immunokonjugate zur Diagnose und/oder Therapie der vaskularisierten Tumoren
US5646250A (en) * 1992-04-17 1997-07-08 Doheny Eye Institute Cadherin polypeptides
CA2111573C (en) * 1992-04-17 2002-11-26 Shintaro Suzuki Cadherin materials and methods
US5597725A (en) * 1992-04-17 1997-01-28 Doheny Eye Institute Cadherin-specific antibodies and hybridoma cell lines
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
US5861499A (en) * 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US5730977A (en) * 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
US20050222037A1 (en) * 1998-05-05 2005-10-06 Adherex Technologies, Inc. Compounds and methods for modulating VE-cadherin-mediated function
WO1999057149A2 (en) * 1998-05-05 1999-11-11 Adherex Technologies, Inc. Compounds and methods for modulating nonclassical cadherin-mediated functions
US20030206902A1 (en) * 2001-03-05 2003-11-06 Fang Liao Ve-cadherin and vegfr-2 antagonists for therapeutic modulation of angiogenesis

Also Published As

Publication number Publication date
US7371574B2 (en) 2008-05-13
JP2003529370A (ja) 2003-10-07
CY1109097T1 (el) 2014-07-02
EP1268799B1 (en) 2009-03-11
EP1268799A2 (en) 2003-01-02
DK1268799T3 (da) 2009-07-06
AU2001249737A1 (en) 2001-10-15
ES2323938T3 (es) 2009-07-28
US20080317750A1 (en) 2008-12-25
CA2404576A1 (en) 2001-10-11
PT1268799E (pt) 2009-05-11
US20020160003A1 (en) 2002-10-31
WO2001075109A2 (en) 2001-10-11
DE60137915D1 (de) 2009-04-23
WO2001075109A3 (en) 2002-05-16
US20080311121A1 (en) 2008-12-18
US20090060909A1 (en) 2009-03-05

Similar Documents

Publication Publication Date Title
CY1109097T1 (el) Ανταγωνιστες αντισωματων ve-καντερινης χωρις αρνητικες επιδρασεις επι αγγειακης διαπερατοτητας
DE69230545D1 (de) Antikörperderivate
DE69735294D1 (de) Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen
DK1064303T3 (da) Monoklonale antistoffer, der er specifikke for det prostataspecifikke membranantigens ekstracellulære domæne
ATE158415T1 (de) Kationisierte antikörper gegen intrazelluläre eiweisse
EP4112723A4 (en) KPC-TYPE CARBAPENEMASE RESISTANT HYBRIDOMA CELL LINE, MONOCLONAL ANTIBODY (MAB) AND USE THEREOF
DE68918497D1 (de) Monoklonale Mäuseantikörper gegen HIV-IP24 und ihre Verwendung in Diagnostika.
DK0554356T3 (da) Monoklonalt antistof
DE60217698D1 (de) Behandlung chronischer gelenkentzündung unter verwendung eines antikörpers gegen das cd3 antigenkomplex
WO2005103698A3 (en) Methods and antibodies for nitrofuran detection
IT1257893B (it) Anticorpi monoclonali che riconoscono un epitopo della p-glicoproteina umana.
DE68921360D1 (de) Monoklonale Antikörper von Mäusen gegen das gp41 Protein von menschlichem Immunmangelsyndrom-Virus.
DE69529744D1 (de) Monoklonale antikörper spezifisch gegen vaskuläres endothelzellartigen endoglyx-1, das antigen selbst und seine verwendungen
ATE465754T1 (de) Nicht-immunsuppresives hiv tat-protein
DE69129582D1 (de) Antikörper gegen menschlichen plasmin-alpha 2-plasmininhibitor-komplex, hybridoma und immunoassay
DE69132144D1 (de) Menschliche phospholipase aktivierender proteinteil
ATE228536T1 (de) Antigene epitope von ige repräsentierenden peptiden auf der b-zell-oberfläche aber nicht auf oberflächen von basophilen
Weinfeld The charge of hypocrisy in Matthew 23 and in Jewish sources
Becker Religious materialities a workshop in the mcdonald institute for archaeological research, university of cambridge
ATE343596T1 (de) Humane monoklonale antikörper gegen inselzellantigen ia-2
Adams THE INFLUENCE OF COUNSELOR RACE, ATTIRE, AND SPEECH STYLE ON BLACK JUVENILE DELINQUENTS'PERCEPTION OF COUNSELOR ATTRACTIVENESS AND ABILITY TO BE WARM, EMPATHIC, AND GENUINE.
DE69111429D1 (de) Monoklonale antikörper, die einen unterschied zwischen nativproteinen und proteinen mit einer modifizierten sequenz machen.
Brater The infantry of intolerance: Analysis of the OCA's campaign rhetoric during Measure 9 (Oregon)
Galimzhanova Conceptual model of outlook in Kazakh art during independence years on the specimen of Rustam Khalin’s creation
GUTIERREZ COORDINATION OF EDUCATIONAL PROGRAMS FOR SPECIAL POPULATIONS AT THE STATE LEVEL DURING A PERIOD OF DEVOLUTION (ORGANIZATIONAL STRUCTURE, TECHNOLOGY, DIFFERENTIATION, TASK UNCERTAINTY)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1268799

Country of ref document: EP